Skip to content

    Recently Viewed

      Listening...

      Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio

      Share Article
      share to

      New Brunswick, NJ (February 8, 2018) -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-resistant prostate cancer. The webcast is intended for investors and other interested parties, and will be available beginning at 5:00p.m EST on Thursday, February 8, 2018.

      The pre-recorded webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, who will recap pivotal Phase 3 apalutamide data, which were featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) 2018 Cancers Symposium. Dr. Lebowitz will also highlight the company’s prostate cancer strategy and portfolio.

      The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.” The webcast duration is approximately 12 minutes and will be available through the end of April.

      ###

      Press Contact:

      Brian Kenny
      (215) 628-7010

      Satu Glawe
      49-172-294-6264

      Investor Contacts:

      Joseph J. Wolk
      (732) 524-1142

      Lesley Fishman
      (732) 5243922

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.